Innorbio Unveils Breakthrough Off-the-Shelf Immune-Trained NK Cell Therapy and Launches Guangzhou Clinic in Nansha

In recent years, the Nansha government of Guangzhou has successively introduced a series of pilot policies for innovative applications in the field of cell therapy, opening up a fast track for the clinical transformation of new technologies. Inspired by the policies such as the "Nansha Plan," the "Nansha Opinions," and the "9 Articles on Biomedicine" in the Nansha District, quasi-unicorn enterprises in the field of cell therapyImbioray (Hangzhou) Biomedical Co., Ltd. officially settles its Clinical Transformation Center in Nansha Guangdong Medical Valley！

On June 20, Imbioray held a grand event at the Guangdong Medical Valley · Nansha Life Science Park in China.Global Launch of Leading Off-the-Shelf Immune-Tolerant NK Cell Application and Imbioray Guangzhou Clinic Opening Ceremony", Imbioray Guangzhou Clinic Officially Sets Sail.

Dr. Zhenwei Miao, Chairman and CEO of Imbioray, Mr. Jiasheng Xie, Vice Chairman of the Nansha District Association for Science and Technology of Guangzhou City, Standing Committee Member of the CPPCC, and Executive President of Guangdong Medical Valley, Mr. Li Gao, President of the Guangdong-Hong Kong-Macao Greater Bay Area Life Science Industry Promotion Association, Dr. Jinqi Huang, Deputy Chief Physician of Guangzhou First People's Hospital, Dr. Shuang Mei, Chief Technology Officer of Imbioray, and Mr. Chen Zhao and Mr. Sucheng Xiong, Co-founders of the Imbioray Medical Research Center.LifeAttended the press conference together.

The Path of Innovation: Pioneering a New Track for NK Cell Therapy

At the press conference,Dr. Zhenwei Miao, Founder of ImbiorayIntroduction to Imbioray's Innovation Journey: Since 2016, Imbioray has been fully committed to the field of NK cell therapy, where there were no existing drugs globally at that time. Unlike traditional CAR-T therapy, Imbioray has chosen a unique technical route – an off-the-shelf immune-tuned NK cell therapy based on antibody-cell conjugation technology without using viral vectors or gene editing. This method not only enhances the killing activity of NK cells but also achieves targeted treatment while avoiding the safety risks associated with gene editing.

After years of research, Imbioray has achieved four technological iterations, breaking through the challenge of large-scale NK cell culture. The company has established a 200-liter system with the world's largest production capacity, utilizing GMP-standardized manufacturing processes, capable of stably supplying over 100 doses per batch.

Currently, Imbioray has built a pipeline of 16 products, four of which have entered the clinical stage. The world's first 5T4-targeted therapy for solid tumors has progressed to Phase II of the registrational clinical trial. Whether in terms of the number of clinical projects or their progress, Imbioray ranks among the top tier in the NK cell field.

Technological Breakthrough:

Establish "Off-the-Shelf" NK Cell Advantages

Compared with traditional cell therapy products, off-the-shelf NK cells break through the limitation of "personalized customization," enabling allogeneic use and large-scale production, which significantly reduces treatment costs and time costs, laying the foundation for cell therapy to move from "niche" to "universal accessibility."

At the event site,Dr. Mei Shuang, Chief Technology Officer of ImbiorayDetailed Introduction to Imbioray's Universal Off-the-Shelf Immune-Conditioned NK Cells Show Great Potential in the Treatment of Solid Tumors, Hematologic Malignancies, and Autoimmune Diseases. Preclinical data and preliminary clinical application cases demonstrate that this technology has significant effects on tumor microenvironment remodeling and immune escape blockade, with the potential to reshape the landscape of cancer treatment.

Imbioray's choice of Nansha, Guangzhou as the launch site for this significant achievement and the location for its first regional clinic highlights Imbioray's strategic determination to deeply cultivate the Greater Bay Area.

Mr. Xie Jiasheng, Vice Chairman of the Nansha District Association for Science and Technology, Standing Committee Member of the CPPCC, and Executive President of Guangdong Medical ValleyIn the speech, it was also mentioned that with the implementation of several major policies, Nansha has taken on a "pioneering pilot" role, becoming the first "experimental field" and "innovation highland" for the cell therapy industry in the Guangdong-Hong Kong-Macao Greater Bay Area. By lowering entry barriers, strengthening financial support, and optimizing regulatory services, Nansha provides full-chain support for cutting-edge fields such as cell therapy and gene technology. The opening of Imbioray Clinic is a vivid footnote to the high-quality development of Nansha's biomedicine industry and a declaration of confidence in Nansha’s future-oriented efforts to build a world-class life science and healthcare industry hub.

This event is not only a showcase of Imbioray's technological achievements and medical layout, but also a microcosm of the innovative development of China's immune cell industry. As the "innovation engine" in the cell field, Imbioray, with the mission of "the light of immunotherapy, illuminating new hope for life," continues to deeply cultivate NK cell therapy technology innovation, focus on breakthroughs in core cell therapy technologies, and promote the standardized and regulated development of the cell therapy industry. In the wave of biopharmaceutical industry innovation, Imbioray is contributing "China's solutions" to the global development of cell therapy with its technical strength and industrial responsibility.

In the future, Guangdong Medical Valley will move forward together with Imbioray, taking advantage of Nansha policies.East Wind, jointly promote the healthy development of the industry, and inject strong momentum into the high-quality development of the biopharmaceutical industry in Nansha District!